1)Rose WC:Taxol:a review of its preclinical in vivo antitumor activity. Anti-Cancer Drug 3:311-321, 1992
2)Yamori T, Sato S, Chikazawa H, et al:Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jpn J Cancer Res 88:1205-1210, 1997
3)Kubota T, Matsuzaki SW, Hoshiya Y et al:Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. J Surg Oncol 64:115-121, 1997
4)吉崎 陽・井筒俊彦・西谷 巖:PaclitaxelのCDDP感受性および耐性ヒト卵巣癌培養細胞に対する効果.日本癌治療学会誌 30:730-739, 1995
5)吉崎 陽・三浦史晴・針生秀樹・他:CDDP感受性およびCDDP耐性ヒト卵巣癌培養細胞に対するpaclitaxelの効果の検討.産婦人科治療 69:1299,1994
6)Hofstra LS, de Vries EG, Willemse PH:Opthalmic toxicity following paclitaxel infusion. Ann Oncol 8:1053, 1997
7)Esmaeli B, Valero V, Ahmadi MA et al:Canalicular stenosis secondary to docetaxel(taxotere):a newly recognized side effect. Ophthalmology 108:994-995, 2001
8)Joshi MM, Garretson BR:Paclitaxel maculopathy. Arch Ophthalmol 125:709-710, 2007
9)Teitelbaum BA, Tresley DJ:Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 80:277-279, 2003
10)Smith SV, Benz MS, Brown DM:Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol 126:1605-1606, 2008
11)Telander DG, Sarraf D:Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 22:151-153, 2007
12)Spirn MJ, Warren FA, Guyer DR et al:Optical coherence tomography findings in nicotinic acid maculopathy. Am J Ophthalmol 135:913-914, 2003